Nerve growth factor as a paradigm of neurotrophins related to Alzheimer's disease
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Converging lines of evidence on the possible connection between NGF signaling and Alzheimer's diseases (AD) are unraveling new facets which could depict this neurotrophin (NTF) in a more central role. AD animal models have provided evidence that a shortage of NGF supply may induce an AD‐like syndrome. In vitro experiments, moreover, are delineating a possible temporal and causal link between APP amiloydogenic processing and altered post‐translational tau modifications. After NGF signaling interruption, the pivotal upstream players of the amyloid cascade (APP, β‐secretase, and active form of γ‐secretase) are up‐regulated, leading to an increased production of amyloid β peptide (Aβ) and to its intracellular aggregation in molecular species of different sizes. Contextually, the Aβ released pool generates an autocrine toxic loop in the same healthy neurons. At the same time tau protein undergoes anomalous, GSKβ‐mediated, phosphorylation at specific pathogenetic sites (Ser262 and Thr 231), caspase(s) and calpain‐ I‐ mediated truncation, detachment from microtubules with consequent cytoskeleton collapse and axonal transport impairment. All these events are inhibited when the amyloidogenic processing is reduced by β and γ secretase inhibitors or anti‐Aβ antibodies and appear to be causally correlated to TrkA, p75CTF, Aβ, and PS1 molecular association in an Aβ‐mediated fashion. In this scenario, the so‐called trophic action exerted by NGF (and possibly also by other neurotrophins) in these targets neurons is actually the result of an anti‐amyloidogenic activity. © 2010 Wiley Periodicals, Inc. Develop Neurobiol 2010
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kuhn, H., Dickinson-Anson, H., & Gage, F. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-06-02027.1996 · Cited by 3,139
Neurotrophins and their receptors: A convergence point for many signalling pathways
Chao, M. V. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1078 · Cited by 2,298 · cited 1×
“Today we know that NTFs are secreted peptides that act as growth factors promoting the differentia- tion, growth, and maintenance of developing neurons, the survival of adult mature neurons and play central roles in synaptic plasticity (Chao, 2003, 2006).”
BackgroundNeurotrophins as synaptic modulators
Poo, M.-M. (2001) · Nature Reviews Neuroscience · doi:10.1038/35049004 · Cited by 1,775
The yin and yang of neurotrophin action
Lu, B., Pang, P. T., & Woo, N. H. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1726 · Cited by 1,356
Long-Lasting Neurotrophin-Induced Enhancement of Synaptic Transmission in the Adult Hippocampus
Kang, H., & Schuman, E. M. (1995) · Science · doi:10.1126/science.7886457 · Cited by 1,354
Gauthier, L. R., Charrin, B. C., Borrell-Pagès, M., Dompierre, J. P., Rangone, H., Cordelières, F. P., De Mey, J., MacDonald, M. E., Leßmann, V., Humbert, S., et al. (2004) · Cell · doi:10.1016/j.cell.2004.06.018 · Cited by 1,178
Figurov, A., Pozzo-Miller, L. D., Olafsson, P., Wang, T., & Lu, B. (1996) · Nature · doi:10.1038/381706a0 · Cited by 1,106
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050 · cited 4×
“After 24 months of ex vivo NGF gene delivery, no long-term adverse effects are found and a marked reduction of the rate of cognitive decline and an increase of cortical glucose metabolic uptake are detected in treated subjects (Tuszynski et al., 2005).”
BackgroundResultInfluentialDifferential Regulation of Dynein and Kinesin Motor Proteins by Tau
Dixit, R., Ross, J. L., Goldman, Y. E., & Holzbaur, E. L. F. (2008) · Science · doi:10.1126/science.1152993 · Cited by 1,012 · cited 2×
“…motor-driven transport in a concentration-dependent manner and differentially modulates the kinesin and dynein activ- ity along microtubule tracks (Dixit et al., 2008), defective intracellular trafficking of cargoes, includ- ing NTFs, could be due to an increased expression level of this…”
BackgroundLee, J., Duan, W., & Mattson, M. P. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01085.x · Cited by 975
Cited by
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061
“Cross talk occurs between APP processing and NGF signaling pathways such that Aβ generation may be altered by NGF signaling (Calissano et al. 2010).”
BackgroundTau Protein Modifications and Interactions: Their Role in Function and Dysfunction
Mietelska-Porowska, A., Wasik, U., Goras, M., Filipek, A., & Niewiadomska, G. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15034671 · Cited by 404
Role of inflammatory molecules in the Alzheimer's disease progression and diagnosis
Bagyinszky, E., Giau, V. V., Shim, K., Suk, K., An, S. S. A., & Kim, S. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.03.031 · Cited by 262
Zimbone, S., Monaco, I., Gianì, F., Pandini, G., Copani, A. G., Giuffrida, M. L., & Rizzarelli, E. (2018) · Aging Cell · doi:10.1111/acel.12684 · Cited by 79
Sanphui, P., Pramanik, S. K., Chatterjee, N., Moorthi, P., Banerji, B., & Biswas, S. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078842 · Cited by 38
“Accumulating evidences also link lack of NGF signaling to altered amloidogenesis and development of Alzheimer’s pathology [22,23].”
BackgroundMethodYilmaz, S. N., Steiner, K., Marksteiner, J., Faserl, K., Villunger, M., Sarg, B., & Humpel, C. (2024) · Biomolecules · doi:10.3390/biom14101326 · Cited by 9
Metadata
- Authors
- Calissano, P., Matrone, C., & Amadoro, G.
- Venue
- Developmental Neurobiology
- Publisher
- Wiley
- Published
- 2010-02-22
- Volume
- 70
- Issue
- 5
- Pages
- 372-383
- ISSN
- 1932-8451 (ISSN-L)
- 1932-846X
- OpenAlex
- W2091721738
- Cited by
- 86
- References
- 26
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.